Mirum Pharmaceuticals, Inc.
mirumpharma.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
38
Active
12
Phase 3
12
Total enrollment
2,648
Pipeline matrix
Showing 16 of 16 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Livmarli Oral Product | — | — | — | — | — | 1 | |
| Brelovitug 300 mg | — | — | — | — | — | 3 | |
| Brelovitug 900 mg | — | — | — | — | — | 2 | |
| Delayed Treatment with Brelovitug 300mg | — | — | — | — | — | 2 | |
| Brelovitug | — | — | — | — | — | 1 | |
| Bulevirtide | — | — | — | — | — | 1 | |
| Bulevirtide 2 mg and Brelovitug - 300 mg | — | — | — | — | — | 1 | |
| Maralixibat | — | — | 9 | ||||
| Volixibat | — | — | — | — | 4 | ||
| Low dose of MRM-3379 | — | — | — | — | — | 1 | |
| Middle Dose of MRM-3379 | — | — | — | — | — | 1 | |
| High dose of MRM-3379 | — | — | — | — | — | 1 | |
| Low dose of MRM-3379 Open-Label | — | — | — | — | — | 1 | |
| [14C]-MRM-3379 | — | — | — | — | — | 1 | |
| Cholbam | — | — | — | — | — | 1 | |
| Livmarli | — | — | — | — | — | 1 |
Next readouts
- 2026-06
- 2026-07
- 2026-08
- 2026-10
- 2027-04
- 2027-06-30
- 2027-08-31
- 2027-10
- 2028-09-20
- 2029-05
Top conditions
- Alagille Syndrome10
- Progressive Familial Intrahepatic Cholestasis4
- Progressive Familial Intrahepatic Cholestasis (PFIC)4
- Non-Alcoholic Steatohepatitis3
- Chronic Hepatitis D Infection3
- Primary Biliary Cirrhosis2
- Healthy Volunteers2
- PBC2
Frequently asked questions about Mirum Pharmaceuticals, Inc.
- How many clinical trials does Mirum Pharmaceuticals, Inc. have on ClinicalTrials.gov?
- Mirum Pharmaceuticals, Inc. is listed as the lead sponsor on 38 clinical trials in ClinicalTrials.gov, 12 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Mirum Pharmaceuticals, Inc.'s trials are in Phase 3?
- 12 of Mirum Pharmaceuticals, Inc.'s trials are in Phase 3, spread across 16 active drug programs.
- What therapeutic areas does Mirum Pharmaceuticals, Inc. focus on?
- Mirum Pharmaceuticals, Inc.'s most-studied conditions on ClinicalTrials.gov are Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis, Progressive Familial Intrahepatic Cholestasis (PFIC), Non-Alcoholic Steatohepatitis, Chronic Hepatitis D Infection.
- When are Mirum Pharmaceuticals, Inc.'s next clinical trial readouts?
- Mirum Pharmaceuticals, Inc. has 10 upcoming primary-completion readouts tracked here; the soonest is “A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)”, expected around 2026-06.